Table 4.

Rifapentine and main metabolite (25-desacetyl rifapentine) concentrations in ELF and ACs

DrugMean ± SD concn (μg/ml) for the following group:
4 h (n = 5)5 h (n = 5)7 h (n = 5)12 (n = 5)24 (n = 5)48 (n = 5)
ACELFACELFACELFACELFACELFACELF
Rifapentine5.0 ± 4.23.2 ± 2.14.8 ± 2.43.7 ± 1.4a5.3 ± 2.5b2.3 ± 1.1c3.7 ± 1.43.0 ± 1.52.9 ± 1.32.0 ± 1.20.6 ± 1.0b0.7 ± 0.7a
25-Desacetyl rifapentine0.9 ± 1.1c0.1 ± 0.1d0.6 ± 0.80.5 ± 0.500.5 ± 0.30.6 ± 0.61.8 ± 1.0d1.5 ± 1.00.8 ± 1.00.6 ± 1.00.2 ± 0.5
  • a For ELF rifapentine concentration in 5-h group versus ELF rifapentine concentration in 48-h group, P < 0.05; all other comparisons were not significant (P > 0.05).

  • b For AC rifapentine concentration in 7-h group versus AC rifapentine concentration in 48-h group, P < 0.05; all other comparisons were not significant (P > 0.05).

  • c None of the differences in AC 25-desacetyl rifapentine concentrations were significant (P > 0.05).

  • d For ELF 25-desacetyl rifapentine concentration in 12-h group versus 25-desacetyl rifapentine concentration in 4-h group, P < 0.05; all other comparisons were not significant.